1Fitzgibbons PL, Henson DE, Hurter RVP, et al. Benign breast changes and the risk for subsequent breast cancer [ J ]. Arch Pathol Lab Med,1998,122(12) :1053 - 1055.
2Tavassoli FA, Devilee P. World Health Organization classification of tumors. Pathology and genetics of tumors of haematopoietic and lymphoid tissues[ M ]. Lyon : IARC Press,2003:60 - 80.
3Lakhani SR, Audretsch W, Cleton-Jensen AM ,et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS) ? [J]. Eur J Cancer,2006,42 ( 14 ) :2205 - 2211.
4Trevathan-Ramirez D. Innovations in breast cancer disease diagnosis[J]. Radiol Technol, 1998,17 (2) : 193 - 203.
5Venta EA. Image-guided biopsy of non-palpable breast lesions [ M ]//Disease of the Breast. Philadelphia: Lippincott William & Wilkins, 1999 : 149 - 164.
7Tavassoli FA. Pathology of the breast. Mc Graw Hill [ M ]. 2nd ed. New York: Mc Graw Hill,1999:494 -504.
8Rosen PP. Rosen' s breast pathology [ M ]. 2nd ed. Philadelphia: Lippincott Williams Wilkins,2001:483 -495.
9Taghian A, Mobiuddin M, Jagsi R,et al. Current perception regarding surgical margin status after breast-conserving therapy : resuits of a survey[J]. Ann Surg, 2005,241 (4) :629 -639.
10Dillon MF, Hill ADK, Quinn CM,et al. A pathological assessment of adequate margin status in breast-conserving therapy [J]. Ann Surg,2006,13 (3) :333 -339.
4Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.J Clin Oncol,2007,25(1):118-145.
5Francis GD,Dimech M,Giles L,et al.Frequency and reliability of oestrogen receptor,progesterone receptor and HER2 in breast carcinoma determined by immunohistochemistry in Australasia:results of the RCPA Quality Assurance Program.J Clin Pathol,2007,60(11):1277-1283.
6Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast caner.J Clin Oncol,2010,28(16):2784-2795.
7Lester SC.Breast//Lester SC.Manual of Surgical Pathology.2nd ed.Boston:Elsevier,2006:239-242.
8Ibrahim M,Dodson A,Barnett S,et al.Potential for falsepositive staining with a rabbit monoclonal antibody to progesterone receptor(SP2):findings of the UK National External Quality Assessment Scheme for immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory.Am J Clin Pathol,2008,129(3):398-409.
9Vance GH,Barry TS,Bloom KJ,et al.Genetic heterogeneity in HER2 testing in breast cancer:panel summary and guidelines.Arch Pathol Lab Med,2009,133(4):611-612.
10Mukai H,Watanabe T,Ando M,et al.Assessment of different criteria for the pathological complete response (pCR) to primary chemotherapy in breast cancer:standardization is needed.Breast Cancer Res Treat,2009,113(1):123-128.
